Neuroendocrine Tumors of the Breast Are Predominantly ER-Positive
Yes, neuroendocrine tumors of the breast typically show ER positivity, with estrogen receptor expression reported in 75.8% to nearly 100% of cases. 1
Key Characteristics of Breast Neuroendocrine Tumors
Hormone Receptor Profile
Breast neuroendocrine tumors (BNETs) demonstrate a predominantly luminal immunophenotype with the following features:
- ER positivity is nearly universal (75.8%-100% of cases) 1
- PR positivity is common (60-80% of cases) 2
- HER2 overexpression is rare 1, 3
- This hormone receptor-positive profile makes them eligible for endocrine therapy according to standard breast cancer guidelines 4
Important Distinction: Two Subtypes with Different ER Patterns
There is a critical distinction between two types of neuroendocrine breast tumors:
Primary Neuroendocrine Tumors (Well-differentiated): These are the classic BNETs with >90% neuroendocrine morphology per WHO 2019 criteria. They show very high ER positivity (75.8-100%) and are typically luminal-type tumors 1
High-Grade Neuroendocrine Carcinomas (NECs): These poorly differentiated tumors show a different pattern - they are predominantly ER-negative/HER2-negative (63%) and behave more aggressively 5. They have distinct molecular features including frequent TP53 (90%) and RB1 (60%) alterations 5
Clinical Implications
For typical BNETs (well-differentiated):
- Treat according to standard hormone receptor-positive breast cancer protocols 3
- Endocrine therapy is the cornerstone of treatment 6, 7
- CDK4/6 inhibitors combined with aromatase inhibitors can be effective in metastatic disease 6
- Prognosis is generally favorable with 5-year disease-free survival of 91.1% 1
For high-grade NECs:
- Despite some ER positivity in a subset, these behave more aggressively
- Limited response to neoadjuvant chemotherapy (no pathologic complete responses observed) 5
- May require different therapeutic approaches given their distinct molecular profile
Common Pitfall to Avoid
Do not assume all neuroendocrine breast tumors are the same. The well-differentiated neuroendocrine tumors are almost always ER-positive and respond to hormonal therapy, while high-grade neuroendocrine carcinomas are frequently ER-negative and have a distinct, more aggressive biology 5. Proper classification according to WHO 2019 criteria (requiring >90% neuroendocrine morphology) is essential for appropriate treatment planning 1.